Rosuvastatin for Intracranial Arterial Stenosis on Magnetic Resonace Angiography

Rosuvastatin for Intracranial Arterial Stenosis on Magnetic Resonace Angiography - Rosuvastatin for Intracranial Arterial Stenosis on Magnetic Resonace Angiography

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016202

Enrollment

Registered

2017-01-20

Start date

2017-01-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intracranial Arterial Stenosis

Interventions

Rosuvastatin (5mg) will be orally administered once daily. Dose of rosuvastatin will be adjusted to control serum LDL-c level under 70 mg/dl (1.8mmol/L). Clopidogrel (50mg or 75mg) will be orally ad

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients aged 30 to 80 years old when providing informed consent Patients with non-cardioembolic ischemic stroke Patients with intracranial arterial stenosis 50% or more than 50% on MRA (supra-clinoidal internal carotid artery, M1 portion of middle cerebral artery, A1 portion of anterior cerebral artery, P1 portion of posterior cerebral artery, or basilar artery) Patients with dyslipidemia (LDL-c mg/dL; 2.6 mmol/L) or under the treatment of dyslipidemia Patients taking clopidogrel as anti-platelet therapy when providing informed consent Patients considered to be able to visit the study site Patients who provided written informed consent

Exclusion criteria

Exclusion criteria: Any hemorrhagic stroke or hemorrhagic infarction Familial hypercholesterolemia Patients with uncontrolled angina pectoris or congestive heart failure Patients with severe liver or renal dysfunction Patients with a malignant tumor requiring treatment Patients with uncontrolled diabetes mellitus Patients with secondary dyslipidemia (due to corticosteroid etc) Patients with a history of myopathy Patients considered by the investigator to be unsuitable for participating in this study

Design outcomes

Primary

Measure	Time frame
Progression of intracranial stenosis after two years	—

Secondary

Measure	Time frame
Any stroke [ischemic stroke, intracerebral hemorrhage, subarachnoid hemorrhage] Ischemic stroke or transient ischemic attack (TIA) Intracerebral hemorrhage or subarachnoid hemorrhage Death from any cause All vascular events (stroke, myocardial infarction, or other vascular events) The change in LDL-c level from baseline The change in HDL-c level from baseline Number of cerebral microbleeds on MRI Carotid intima-media thickness Ankle brachial index Brachial-ankle pulse wave velocity Adverse events and adverse drug reactions	—

Measure

Time frame

Any stroke [ischemic stroke, intracerebral hemorrhage, subarachnoid hemorrhage] Ischemic stroke or transient ischemic attack (TIA) Intracerebral hemorrhage or subarachnoid hemorrhage Death from any cause All vascular events (stroke, myocardial infarction, or other vascular events) The change in LDL-c level from baseline The change in HDL-c level from baseline Number of cerebral microbleeds on MRI Carotid intima-media thickness Ankle brachial index Brachial-ankle pulse wave velocity Adverse events and adverse drug reactions

—

Countries

Japan

Contacts

Public ContactHitoshi Aizawa

Tokyo Medical University Department of Neurology

haizawa@tokyo-med.ac.jp+81-3-3342-6111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026